Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Stemtech (STEK) Shares Outstanding (Diluted Average) (2020 - 2025)

Historic Shares Outstanding (Diluted Average) for Stemtech (STEK) over the last 6 years, with Q3 2025 value amounting to $150.1 million.

  • Stemtech's Shares Outstanding (Diluted Average) changed N/A to $150.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.1 million, marking a year-over-year change of. This contributed to the annual value of $118.7 million for FY2024, which is 4220.47% up from last year.
  • Stemtech's Shares Outstanding (Diluted Average) amounted to $150.1 million in Q3 2025.
  • In the past 5 years, Stemtech's Shares Outstanding (Diluted Average) registered a high of $150.1 million during Q3 2025, and its lowest value of $19.1 million during Q3 2021.
  • Over the past 5 years, Stemtech's median Shares Outstanding (Diluted Average) value was $58.3 million (recorded in 2023), while the average stood at $74.7 million.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first skyrocketed by 27907.33% in 2021, then skyrocketed by 2200.3% in 2025.
  • Over the past 5 years, Stemtech's Shares Outstanding (Diluted Average) (Quarter) stood at $35.3 million in 2021, then skyrocketed by 30.31% to $46.0 million in 2022, then soared by 81.4% to $83.5 million in 2023, then soared by 42.2% to $118.7 million in 2024, then rose by 26.46% to $150.1 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $150.1 million for Q3 2025, versus $142.4 million for Q2 2025 and $118.7 million for Q1 2025.